Hameln rds is a well recognised pharmaceutical service provider

for health-care industry. We focus on different steps during development and production of pharmaceutical products. We are covering analytical and galenical development of pharmaceuticals, Quality Control Services (stabilities and batch release) and development and GMP manufacturing of APIs.

  • 2014

    After the ownership changes have been realised within hameln pharmaceuticals gmbh and hameln rds gmbh, today we are a part of hameln group with following companies:
  • 2014

    Specialised in marketing of products for acute treatments
    • Germany based office
  • 2014

    Specialised in marketing of products for acute treatments

    • UK based office

  • 2014

    Development and all health care market services

    • Slovakia based office

  • 2007

    Name of the company has been changed into hameln rds a.s

  • 2006

    Acquisition of 100% shares of VULM a.s. by hameln rds gmbh

  • 1996

    Transformation of the Drug Research Institute, š.p., (state enterprise) into VULM, a.s. (joint-stock company) with approximately 165 employees. Slovakofarma, a.s. became the main shareholder having 51% of the equity

  • 1991

    The Section of Biological research and the Section of Analytical Chemistry were awarded with the Certificate of Good Laboratory Praxis (GLP). The Institute became a first organisation obtaining GLP Certificate in Slovakia

  • 1989

    Finishing of the construction of new buildings in Modra and organisation of the official opening ceremony. At this time, Institute had 395 employees

  • 1977

    Decision of the Ministry of Health to move the main seat of the Institute from Hlohovec to Modra

  • 1972

    Foundation of the Drug Research Institute as an independent Institution of Spofa having its office location in Hlohovec with 54 employees